NasdaqGS - Nasdaq Real Time Price USD

Ionis Pharmaceuticals, Inc. (IONS)

32.60

+0.07

+(0.22%)

At close: May 14 at 4:00:00 PM EDT

Ionis Pharmaceuticals, Inc. (IONS): Among Billionaire Glenn Russell Dubin’s Stock Picks with Huge Upside Potential

We recently published a list of Billionaire Glenn Russell Dubin’s 10 Stock Picks with Huge Upside Potential. In this article, we are going to take a look at where Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) stands against Billionaire Glenn Russell Dubin’s other stock picks with huge upside potential. Glenn Russell Dubin is one of the industry’s most […]

Insider Monkey 3 days ago

IONS
+0.22%
Ionis to host 2025 virtual Annual Meeting of Stockholders

CARLSBAD, Calif., May 06, 2025--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2025 virtual Annual Meeting of Stockholders followed by a general corporate update on Thursday, June 5, 2025.

Business Wire 8 days ago

IONS
+0.22%
Analysts Just Made A Sizeable Upgrade To Their Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Forecasts

Shareholders in Ionis Pharmaceuticals, Inc. ( NASDAQ:IONS ) may be thrilled to learn that the analysts have just...

Simply Wall St. 9 days ago

IONS
+0.22%
Ionis Pharmaceuticals First Quarter 2025 Earnings: Beats Expectations

Ionis Pharmaceuticals ( NASDAQ:IONS ) First Quarter 2025 Results Key Financial Results Revenue: US$132.0m (up 11% from...

Simply Wall St. 12 days ago

IONS
+0.22%
Ionis Pharmaceuticals Lifts Revenue Forecast After Strong Q1, Oppenheimer Says

Ionis Pharmaceuticals (IONS) reported strong Q1 financial results, driven by increased commercial an

PREMIUM
MT Newswires 13 days ago

IONS
+0.22%
Ionis Q1 Earnings and Sales Top Estimates, Stock Gains on Raised '25 View

IONS reports better-than-expected first-quarter results. The company raises its sales guidance for 2025 by more than 20% on the back of two new licensing deals.

Zacks 13 days ago

IONS
+0.22%

AZN
Ionis Pharmaceuticals Inc (IONS) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ...

Ionis Pharmaceuticals Inc (IONS) reports a 10% revenue increase and raises 2025 guidance, driven by successful product launches and strategic initiatives.

GuruFocus.com 14 days ago

IONS
+0.22%
Q1 2025 Ionis Pharmaceuticals Inc Earnings Call

Q1 2025 Ionis Pharmaceuticals Inc Earnings Call

Thomson Reuters StreetEvents 14 days ago

IONS
+0.22%
Ionis Pharmaceuticals (IONS) Reports Q1 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Ionis Pharmaceuticals (IONS) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks 14 days ago

IONS
+0.22%
Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Tops Revenue Estimates

Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 32.43% and 9.86%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks 14 days ago

IONS
+0.22%
Ionis Pharmaceuticals: Q1 Earnings Snapshot

The Carlsbad, California-based company said it had a loss of 93 cents per share. Losses, adjusted for stock option expense, were 75 cents per share. The results beat Wall Street expectations.

Associated Press Finance 14 days ago

IONS
+0.22%
Ionis reports first quarter 2025 financial results

CARLSBAD, Calif., April 30, 2025--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the "Company") today reported financial results for the first quarter ended March 31, 2025.

Business Wire 14 days ago

IONS
+0.22%
New Harris Poll findings reveal HAE patients are unsatisfied with current prophylactic treatment options, with over 90% interested in trying new therapies

CARLSBAD, Calif., April 29, 2025--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced results from a new survey showing that 91% of surveyed adults living with hereditary angioedema (HAE) were interested in trying a new prophylactic therapy, with nearly two-thirds (65%) reporting they haven’t yet found the best treatment option for them. The Ionis-sponsored survey was conducted online by The Harris Poll among 150 adults living with HAE and 228 allergists/immunologists who see HAE patients

Business Wire 15 days ago

IONS
+0.22%
Amneal Pharmaceuticals (AMRX) Earnings Expected to Grow: Should You Buy?

Amneal (AMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 19 days ago

IONS
+0.22%
Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 21 days ago

IONS
+0.22%
Ionis to hold first quarter 2025 financial results webcast

CARLSBAD, Calif., April 16, 2025--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, April 30th at 11:30 a.m. Eastern Time to discuss its first quarter 2025 financial results.

Business Wire 28 days ago

IONS
+0.22%
Ionis Pharmaceuticals (IONS) Surges 8.9%: Is This an Indication of Further Gains?

Ionis Pharmaceuticals (IONS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks last month

IONS
+0.22%

USNA
Ionis to host expert panel discussion on sHTG

CARLSBAD, Calif., April 03, 2025--Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today it will host a webinar on Monday, April 14th at 11:00 a.m. ET focused on the risks, clinical presentation and significant unmet medical needs associated with severe hypertriglyceridemia (sHTG). Key thought leaders in lipidology, cardiology and endocrinology will join Sam Tsimikas, M.D., senior vice president, global cardiovascular development, Ionis, for a live discussion followed by a brief Q&A session.

Business Wire last month

IONS
+0.22%
Ionis to present at upcoming investor conferences

CARLSBAD, Calif., March 31, 2025--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences:

Business Wire last month

IONS
+0.22%
Catalyst (CPRX) Up 14.7% Since Last Earnings Report: Can It Continue?

Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks last month

CPRX

IONS
+0.22%

Performance Overview

Return	IONS	S&P 500 (^GSPC)
YTD	-6.75%	+0.19%
1-Year	-14.82%	+12.31%
3-Year	-9.65%	+46.44%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Ionis Pharmaceuticals, Inc. (IONS)

Ionis Pharmaceuticals, Inc. (IONS): Among Billionaire Glenn Russell Dubin’s Stock Picks with Huge Upside Potential

Ionis to host 2025 virtual Annual Meeting of Stockholders

Analysts Just Made A Sizeable Upgrade To Their Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Forecasts

Ionis Pharmaceuticals First Quarter 2025 Earnings: Beats Expectations

Ionis Pharmaceuticals Lifts Revenue Forecast After Strong Q1, Oppenheimer Says

Ionis Q1 Earnings and Sales Top Estimates, Stock Gains on Raised '25 View

Ionis Pharmaceuticals Inc (IONS) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ...

Q1 2025 Ionis Pharmaceuticals Inc Earnings Call

Ionis Pharmaceuticals (IONS) Reports Q1 Earnings: What Key Metrics Have to Say

Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Tops Revenue Estimates

Ionis Pharmaceuticals: Q1 Earnings Snapshot

Ionis reports first quarter 2025 financial results

New Harris Poll findings reveal HAE patients are unsatisfied with current prophylactic treatment options, with over 90% interested in trying new therapies

Amneal Pharmaceuticals (AMRX) Earnings Expected to Grow: Should You Buy?

Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Ionis to hold first quarter 2025 financial results webcast

Ionis Pharmaceuticals (IONS) Surges 8.9%: Is This an Indication of Further Gains?

Ionis to host expert panel discussion on sHTG

Ionis to present at upcoming investor conferences

Catalyst (CPRX) Up 14.7% Since Last Earnings Report: Can It Continue?

Performance Overview